Cantuzumab Ravtansine provides an antibody-drug conjugate (ADC) targeting CanAg for cancer and oncology research and specifically combines a CanAg-directed monoclonal antibody with the maytansinoid payload DM4, supporting studies of antigen-targeted cytotoxicity and ADC mechanisms.
Key Features and Benefits
- CanAg-Targeting ADC: Combines a CanAg-directed monoclonal antibody with a cytotoxic maytansinoid payload specifically for targeted cancer research.
- CanAg Recognition: Supports studies specifically involving CanAg expression, antibody binding, cellular uptake, and tumor-targeting mechanisms.
- DM4 Payload: Contains the maytansinoid DM4, a potent microtubule-disrupting agent used in ADC research.
- Targeted Payload Delivery: Supports investigation of antibody-mediated delivery of DM4 to CanAg-expressing cancer cells.
- Microtubule Disruption: DM4 interferes with microtubule function, supporting studies of ADC-mediated cytotoxic mechanisms.
- ADC Research Platform: Enables investigation of target engagement, internalization, payload activity, and cellular response.
- Cancer Research: Supports studies involving CanAg-expressing tumor models and antigen-directed cancer targeting.
Applications
- CanAg-Positive Cancer Research: Supports studies of cancers expressing the CanAg tumor-associated antigen.
- ADC Research: Useful for investigating antibody targeting, cellular uptake, payload delivery, and cytotoxic activity.
- Cancer Biology Research: Supports investigation of CanAg expression and antigen-directed cellular responses.
- Targeted Cancer Therapy Research: Especially useful for studying antibody-mediated delivery of maytansinoid payloads to cancer cells.
- Cell-Based Cancer Assays: Supports evaluation of ADC binding, internalization, cytotoxic response, and target-dependent activity.
- Mechanism-of-Action Studies: Supports investigation of CanAg targeting and DM4-mediated microtubule disruption.
- Comparative ADC Research: Useful for comparing antibody targets, linkers, payloads, and ADC performance.
Storage and Handling
- Storage: Store according to the product specification under recommended temperature conditions. Protect from excessive heat and repeated freeze-thaw cycles.
- Handling: Handle using appropriate procedures for antibody-drug conjugates and cytotoxic research materials. Maintain conditions that preserve protein and conjugate stability.
Cantuzumab Ravtansine combines CanAg-directed targeting with the cytotoxic DM4 payload and specifically supports CanAg-positive cancer research, ADC development, targeted drug delivery, and oncology studies.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.
